[Ip-health] Compulsory Licensing vs. International Procurement

Justin Mendoza justin.mendoza at yale.edu
Mon Apr 20 06:19:04 PDT 2015

I stumbled upon this interesting piece the other day while researching for 
a project I'm working on. Thought I would share it here, and see if anyone 
had put out a response to it, or had any thoughts on the data. 

I found this line from the discussion most interesting: "The compulsory 
licensing price disadvantage was worst for those countries that were less 
well off in terms of Human Development Index score—the very countries that 
most need to save money."

Link (apologies for the pay wall, they didn't publish open source): 

Compulsory licensing often did not produce lower prices for antiretrovirals 
compared to international procurement.
Beall RF 
1, Kuhn R 
2, Attaran A 

ABSTRACT Compulsory licensing has been widely suggested as a legal 
mechanism for bypassing patents to introduce lower-cost generic 
antiretrovirals for HIV/AIDS in developing countries. Previous studies 
found that compulsory licensing can reduce procurement prices for drugs, 
but it is unknown how the resulting prices compare to procurements through 
the Global Fund to Fight AIDS, Tuberculosis, and Malaria; UNICEF; and other 
international channels. For this study we systematically constructed a 
case-study database of compulsory licensing activity for antiretrovirals 
and compared compulsory license prices to those in the World Health 
Organization’s (WHO’s) Global Price Reporting Mechanism and the Global 
Fund’s Price and Quality Reporting Tool. Thirty compulsory license cases 
were analyzed with 673 comparable procurements from WHO and Global Fund 
data. Compulsory license prices exceeded the median international 
procurement prices in nineteen of the thirty case studies, often with a 
price gap of more than 25 percent. Compulsory licensing often delivered 
suboptimal value when compared to the alternative of international 
procurement, especially when used by low-income countries to manufacture 
medicines locally. There is an ongoing need for multilateral and charitable 
actors to work collectively with governments and medicine suppliers on 
policy options.
Wishing the best,

Justin Mendoza
Yale | School of Public Health
MPH Candidate *2015* | Health Policy
E: justin.mendoza at yale.edu 
C: 269-762-2073 | @justindmendoza <https://twitter.com/JustinDMendoza>
Linkedin Available Here <http://linkd.in/1o9jLDn>

More information about the Ip-health mailing list